Washington Post, June 1, 2023: CMS announces that Medicare will cover FDA fully approved Alzheimer’s treatments for patients in a registry that will evaluate safety and efficacy. NCHR explains why this is essential to learn which patients are most likely to benefit and which are most likely to be harmed.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Could new drugs for early Alzheimer’s really signal the end of dementia? These women say ‘breakthrough’ medicines have halted their mental decline. But do side-effects – and cost – outweigh the benefits…
Daily Mail, May 30, 2023: The Daily Mail reports on new Alzheimer’s drugs that are approved in the US but not in the UK. Dr. Zuckerman & other experts ask: Are they worth the costs or the risks? Patients want access but do these drugs really work? Mild cognitive impairment can change daily without treatment – we all have good days and bad days.
Read More »Under pressure from patients, FDA faces tough choices on experimental gene therapy
Boston Globe, May 22, 2023: Boston Globe quotes NCHR and other experts explaining why we are concerned that Sarepta’s gene therapy for Duchenne Muscular Dystrophy isn’t proven to work and has substantial risks. If it doesn’t work, patients who use it will not be able to try other, potentially better gene therapies in the future.
Read More »Unproven Drugs Reap Billions for Years After Taking FDA Shortcut
Bloomberg News, May 12, 2023: Accelerated approval of Sarepta drugs for Duchenne muscular dystrophy makes billions of dollars for the company even though the drugs aren’t proven to work. We call Sarepta decisions a poster child for inexcusable FDA lack of oversight or enforcement.
Read More »FDA advisers recommend accelerated approval of a Sarepta gene therapy
Boston Globe, May 12, 2023: FDA advisers recommended accelerated approval of Sarepta gene therapy for Duchenne Muscular Dystrophy, despite questionable results and worrisome risks. We testified that lowering FDA standards harms all families, and that Duchenne patients deserve free access to affordable treatments until drugs are proven to work.
Read More »